These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35542836)

  • 1. Novel stereoselective syntheses of
    Li FL; Yu JP; Ding W; Sun MM; He YG; Zhu XL; Liu SL; Shi XX
    RSC Adv; 2019 Dec; 9(72):42077-42084. PubMed ID: 35542836
    [No Abstract]   [Full Text] [Related]  

  • 2. Concise syntheses of potent chaperone drug candidates, N-octyl-4-epi-β-valinenamine (NOEV) and its 6-deoxy derivative, from (+)-proto-quercitol.
    Kuno S; Takahashi A; Ogawa S
    Carbohydr Res; 2013 Mar; 368():8-15. PubMed ID: 23314299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation of quercitols into 4-methylenecyclohex-5-ene-1,2,3-triol derivatives, precursors for the chemical chaperones N-octyl-4-epi-β-valienamine (NOEV) and N-octyl-β-valienamine (NOV).
    Kuno S; Takahashi A; Ogawa S
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7189-92. PubMed ID: 22001090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities.
    Suzuki Y; Ogawa S; Sakakibara Y
    Perspect Medicin Chem; 2009 May; 3():7-19. PubMed ID: 19812739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Stereoselective Syntheses of (+)-Streptol and (-)-1
    Zhu XL; Luo YQ; Wang L; Huang YK; He YG; Xie WJ; Liu SL; Shi XX
    ACS Omega; 2021 Jul; 6(26):17103-17112. PubMed ID: 34250367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.
    Hossain MA; Higaki K; Shinpo M; Nanba E; Suzuki Y; Ozono K; Sakai N
    Brain Dev; 2016 Feb; 38(2):175-80. PubMed ID: 26259553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic chaperone effect of N-octyl 4-epi-β-valienamine on murine G(M1)-gangliosidosis.
    Suzuki Y; Ichinomiya S; Kurosawa M; Matsuda J; Ogawa S; Iida M; Kubo T; Tabe M; Itoh M; Higaki K; Nanba E; Ohno K
    Mol Genet Metab; 2012 May; 106(1):92-8. PubMed ID: 22436580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient and Highly Stereoselective Syntheses of (+)-
    Zhu XL; Wang L; Luo YQ; He YG; Li FL; Sun MM; Liu SL; Shi XX
    ACS Omega; 2020 Feb; 5(4):1813-1821. PubMed ID: 32039317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.
    Higaki K; Li L; Bahrudin U; Okuzawa S; Takamuram A; Yamamoto K; Adachi K; Paraguison RC; Takai T; Ikehata H; Tominaga L; Hisatome I; Iida M; Ogawa S; Matsuda J; Ninomiya H; Sakakibara Y; Ohno K; Suzuki Y; Nanba E
    Hum Mutat; 2011 Jul; 32(7):843-52. PubMed ID: 21520340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantiospecific Syntheses of Valienamine and 2-epi-Valienamine(1).
    Shing TK; Li TY; Kok SH
    J Org Chem; 1999 Mar; 64(6):1941-1946. PubMed ID: 11674286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.
    Hossain MA; Higaki K; Saito S; Ohno K; Sakuraba H; Nanba E; Suzuki Y; Ozono K; Sakai N
    J Hum Genet; 2015 Sep; 60(9):539-45. PubMed ID: 26108143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of biologically active carbaglycosylamines: From glycosidase inhibitors to pharmacological chaperones.
    Ogawa S; Kuno S; Toyokuni T
    Proc Jpn Acad Ser B Phys Biol Sci; 2022; 98(7):336-360. PubMed ID: 35908956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical chaperone therapy for GM1-gangliosidosis.
    Suzuki Y
    Cell Mol Life Sci; 2008 Feb; 65(3):351-3. PubMed ID: 18202827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical chaperone therapy: luciferase assay for screening of β-galactosidase mutations.
    Li L; Higaki K; Ninomiya H; Luan Z; Iida M; Ogawa S; Suzuki Y; Ohno K; Nanba E
    Mol Genet Metab; 2010 Dec; 101(4):364-9. PubMed ID: 20826101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.
    Matsuda J; Suzuki O; Oshima A; Yamamoto Y; Noguchi A; Takimoto K; Itoh M; Matsuzaki Y; Yasuda Y; Ogawa S; Sakata Y; Nanba E; Higaki K; Ogawa Y; Tominaga L; Ohno K; Iwasaki H; Watanabe H; Brady RO; Suzuki Y
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15912-7. PubMed ID: 14676316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-galactosidase deficiency: an approach to chaperone therapy.
    Suzuki Y
    J Inherit Metab Dis; 2006; 29(2-3):471-6. PubMed ID: 16763919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: Powerful β-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal β-galactosidase.
    Thonhofer M; Weber P; Santana AG; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1438-42. PubMed ID: 26838810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.
    Lin H; Sugimoto Y; Ohsaki Y; Ninomiya H; Oka A; Taniguchi M; Ida H; Eto Y; Ogawa S; Matsuzaki Y; Sawa M; Inoue T; Higaki K; Nanba E; Ohno K; Suzuki Y
    Biochim Biophys Acta; 2004 Aug; 1689(3):219-28. PubMed ID: 15276648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast screening for chaperone therapy in beta-galactosidosis.
    Iwasaki H; Watanabe H; Iida M; Ogawa S; Tabe M; Higaki K; Nanba E; Suzuki Y
    Brain Dev; 2006 Sep; 28(8):482-6. PubMed ID: 16617000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.